A rare case of synchronous multiple primary lung cancer with different responses to gefitinib

Differentiating multiple primary lung cancer (MPLC) from lung metastasis is important, and the pathology and gene mutations may be different between the tumors. A lung biopsy to differentiate lesions should be considered, especially when the response of different tumors to treatment is distinct.

Detalles Bibliográficos
Autores principales: Liao, Che-Chi, Lin, Yu-Sen, Lin, Yu-Chao, Cheng, Chiao-Jen, Chen, Shuo-Chueh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7596341/
https://www.ncbi.nlm.nih.gov/pubmed/33145160
http://dx.doi.org/10.1016/j.rmcr.2020.101270

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7596341/
https://www.ncbi.nlm.nih.gov/pubmed/33145160
http://dx.doi.org/10.1016/j.rmcr.2020.101270

Ejemplares similares